Elagolix sodium

Overview

Elagolix is a selective gonadotropin-releasing hormone receptor (GnRHR) antagonist with KD of 54 pM. It is in phase III clinical trials for the treatment of endometriosis and uterine leiomyoma. Elagolix was also under investigation for the treatment of prostate cancer and benign prostatic hyperplasia, but development for these indications was ultimately not pursued.

Application

Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | GNRH Receptor

Product Information

• Catalog No.: B0084-354739
• CAS No.: 832720-36-2
• Molecular Formula: C32H29F5N3NaO5
• Molecular Weight: 653.58
• Purity: 98%
• Storage: -20°C Freezer
• Solubility: Soluble in DMSO

Source

Original product source